Cargando…

More than a marker: potential pathogenic functions of MAP2

Microtubule-associated protein 2 (MAP2) is the predominant cytoskeletal regulator within neuronal dendrites, abundant and specific enough to serve as a robust somatodendritic marker. It influences microtubule dynamics and microtubule/actin interactions to control neurite outgrowth and synaptic funct...

Descripción completa

Detalles Bibliográficos
Autores principales: DeGiosio, Rebecca A., Grubisha, Melanie J., MacDonald, Matthew L., McKinney, Brandon C., Camacho, Carlos J., Sweet, Robert A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9525131/
https://www.ncbi.nlm.nih.gov/pubmed/36187353
http://dx.doi.org/10.3389/fnmol.2022.974890
_version_ 1784800642952331264
author DeGiosio, Rebecca A.
Grubisha, Melanie J.
MacDonald, Matthew L.
McKinney, Brandon C.
Camacho, Carlos J.
Sweet, Robert A.
author_facet DeGiosio, Rebecca A.
Grubisha, Melanie J.
MacDonald, Matthew L.
McKinney, Brandon C.
Camacho, Carlos J.
Sweet, Robert A.
author_sort DeGiosio, Rebecca A.
collection PubMed
description Microtubule-associated protein 2 (MAP2) is the predominant cytoskeletal regulator within neuronal dendrites, abundant and specific enough to serve as a robust somatodendritic marker. It influences microtubule dynamics and microtubule/actin interactions to control neurite outgrowth and synaptic functions, similarly to the closely related MAP Tau. Though pathology of Tau has been well appreciated in the context of neurodegenerative disorders, the consequences of pathologically dysregulated MAP2 have been little explored, despite alterations in its immunoreactivity, expression, splicing and/or stability being observed in a variety of neurodegenerative and neuropsychiatric disorders including Huntington’s disease, prion disease, schizophrenia, autism, major depression and bipolar disorder. Here we review the understood structure and functions of MAP2, including in neurite outgrowth, synaptic plasticity, and regulation of protein folding/transport. We also describe known and potential mechanisms by which MAP2 can be regulated via post-translational modification. Then, we assess existing evidence of its dysregulation in various brain disorders, including from immunohistochemical and (phospho) proteomic data. We propose pathways by which MAP2 pathology could contribute to endophenotypes which characterize these disorders, giving rise to the concept of a “MAP2opathy”—a series of disorders characterized by alterations in MAP2 function.
format Online
Article
Text
id pubmed-9525131
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95251312022-10-01 More than a marker: potential pathogenic functions of MAP2 DeGiosio, Rebecca A. Grubisha, Melanie J. MacDonald, Matthew L. McKinney, Brandon C. Camacho, Carlos J. Sweet, Robert A. Front Mol Neurosci Molecular Neuroscience Microtubule-associated protein 2 (MAP2) is the predominant cytoskeletal regulator within neuronal dendrites, abundant and specific enough to serve as a robust somatodendritic marker. It influences microtubule dynamics and microtubule/actin interactions to control neurite outgrowth and synaptic functions, similarly to the closely related MAP Tau. Though pathology of Tau has been well appreciated in the context of neurodegenerative disorders, the consequences of pathologically dysregulated MAP2 have been little explored, despite alterations in its immunoreactivity, expression, splicing and/or stability being observed in a variety of neurodegenerative and neuropsychiatric disorders including Huntington’s disease, prion disease, schizophrenia, autism, major depression and bipolar disorder. Here we review the understood structure and functions of MAP2, including in neurite outgrowth, synaptic plasticity, and regulation of protein folding/transport. We also describe known and potential mechanisms by which MAP2 can be regulated via post-translational modification. Then, we assess existing evidence of its dysregulation in various brain disorders, including from immunohistochemical and (phospho) proteomic data. We propose pathways by which MAP2 pathology could contribute to endophenotypes which characterize these disorders, giving rise to the concept of a “MAP2opathy”—a series of disorders characterized by alterations in MAP2 function. Frontiers Media S.A. 2022-09-16 /pmc/articles/PMC9525131/ /pubmed/36187353 http://dx.doi.org/10.3389/fnmol.2022.974890 Text en Copyright © 2022 DeGiosio, Grubisha, MacDonald, McKinney, Camacho and Sweet. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Molecular Neuroscience
DeGiosio, Rebecca A.
Grubisha, Melanie J.
MacDonald, Matthew L.
McKinney, Brandon C.
Camacho, Carlos J.
Sweet, Robert A.
More than a marker: potential pathogenic functions of MAP2
title More than a marker: potential pathogenic functions of MAP2
title_full More than a marker: potential pathogenic functions of MAP2
title_fullStr More than a marker: potential pathogenic functions of MAP2
title_full_unstemmed More than a marker: potential pathogenic functions of MAP2
title_short More than a marker: potential pathogenic functions of MAP2
title_sort more than a marker: potential pathogenic functions of map2
topic Molecular Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9525131/
https://www.ncbi.nlm.nih.gov/pubmed/36187353
http://dx.doi.org/10.3389/fnmol.2022.974890
work_keys_str_mv AT degiosiorebeccaa morethanamarkerpotentialpathogenicfunctionsofmap2
AT grubishamelaniej morethanamarkerpotentialpathogenicfunctionsofmap2
AT macdonaldmatthewl morethanamarkerpotentialpathogenicfunctionsofmap2
AT mckinneybrandonc morethanamarkerpotentialpathogenicfunctionsofmap2
AT camachocarlosj morethanamarkerpotentialpathogenicfunctionsofmap2
AT sweetroberta morethanamarkerpotentialpathogenicfunctionsofmap2